EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Cited by (1,066)

Items 501–600 of 1,066

1. Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma
   William M. Lin, Alissa C. Baker, Rameen Beroukhim, Wendy Winckler, Whei Feng, Jennifer M. Marmion, Elisabeth Laine, Heidi E. Greulich, Hsiuyi Tseng, Casey Gates et al. · 2008 · Cancer Research
2. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
   Flaherty, Keith T., Gray, Robert J., Chen, Alice P., Li, Shuli, McShane, Lisa M., Patton, David, Hamilton, Stanley R., Williams, P. Mickey, Iafrate, A. John, Sklar, Jeffrey et al. · 2020 · Journal of Clinical Oncology
3. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
   Ercan, Dalia, Xu, Chunxiao, Yanagita, Masahiko, Monast, Calixte S., Pratilas, Christine A., Montero, Joan, Butaney, Mohit, Shimamura, Takeshi, Sholl, Lynette, Ivanova, Elena V. et al. · 2012 · Cancer Discovery
4. Genomics and the Continuum of Cancer Care
   Ultan McDermott, James R. Downing, Michael R. Stratton · 2011 · New England Journal of Medicine
5. Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion
   Victoria M. Rimkunas, Katherine E. Crosby, Daiqiang Li, Yerong Hu, Meghan E. Kelly, Ting‐Lei Gu, Jennifer S. Mack, Matthew R. Silver, Xinmin Zhou, Herbert Haack · 2012 · Clinical Cancer Research
6. Mutations and addiction to EGFR: the Achilles ‘heal’ of lung cancers?
   Adi F. Gazdar, Hisayuki Shigematsu, Joachim Herz, John Dorrance Minna · 2004 · Trends in Molecular Medicine
7. Ruthenium complexes can target determinants of tumour malignancy
   Alberta Bergamo, Gianni Sava · 2007 · Dalton Transactions
8. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
   Y.-L. Wu, D. Planchard, Shun Lü, Hao Sun, N. Yamamoto, Dongwook Kim, Daniel Shao-Weng Tan, James Chih‐Hsin Yang, M. Azrif, Tetsuya Mitsudomi et al. · 2018 · Annals of Oncology
9. Hepatocellular Carcinoma: Molecular Pathways and New Therapeutic Targets
   Lewis Rowland Roberts, Gregory James Gores · 2005 · Seminars in Liver Disease
10. Molecularly targeted cancer therapy: some lessons from the past decade
    Min Huang, Aijun Shen, Jian Ding, Meiyu Geng · 2013 · Trends in Pharmacological Sciences
11. Pharmacogenomics: Challenges and Opportunities
    Dan M. Roden, Russ Biagio Altman, N L Benowitz, David Alastair Flockhart, Kathleen M. Giacomini, Julie A. Johnson, Ronald M. Krauss, Howard L. McLeod, Mark J. Ratain, Mary V. Relling et al. · 2006 · Annals of Internal Medicine
12. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program
    J. Han van Krieken, Andreas Jung, Thomas Kirchner, Fátima Carneiro, Raquel Seruca, Fred T. Bosman, Philip Quirke, Jean–François Fléjou, Tine Plato Hansen, Gert D. Hertogh et al. · 2008 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
13. Non-invasive decision support for NSCLC treatment using PET/CT radiomics
    Wei Mu, Lei Jiang, Jianyuan Zhang, Yu Shi, Jhanelle E. Gray, Ilke Tunali, Chao Gao, Yingying Sun, Jie Tian, Xinming Zhao et al. · 2020 · Nature Communications
14. Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus
    Gregory J. Riely, Mark G. Kris, Binsheng Zhao, Tim J. Akhurst, Daniel T. Milton, Erin Moore, Leslie B. Tyson, William J. Pao, Naiyer A. Rizvi, Lawrence Howard Schwartz et al. · 2007 · Clinical Cancer Research
15. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer
    Michael Krypuy, Genni M Newnham, David Morgan Thomas, Matthew Conron, Alexander Dobrovic · 2006 · BMC Cancer
16. Personalized Medicine: Recent Progress in Cancer Therapy
    Valentina Gambardella, Noelia Tarazona, Juan Miguel Cejalvo, Pasquale Lombardi, Marisol Huerta, Susana Roselló, Tania Fleitas, Desamparados Roda, Andrès M.R. Cervantes · 2020 · Cancers
17. Novel Prognostic Value of Nuclear Epidermal Growth Factor Receptor in Breast Cancer
    Hui‐Wen Lo, Weiya Xia, Yongkun Wei, Mohamed Ali‐Seyed, Shiu-Feng Kathy Huang, Mien‐Chie Hung · 2005 · Cancer Research
18. EGFR Nuclear Translocation Modulates DNA Repair following Cisplatin and Ionizing Radiation Treatment
    Gianmaria Liccardi, John Anthony Hartley, Daniel Hochhauser · 2011 · Cancer Research
19. Establishment of Patient-Derived Non–Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers
    Iduna Fichtner, Jana Rolff, Richie Soong, Jens Hoffmann, Stefanie Hammer, Anette Sommer, Michael Becker, Johannes Merk · 2008 · Clinical Cancer Research
20. Synthesis and in vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: Search for anticancer agent
    Malleshappa N. Noolvi, Harun Patel, Varun Bhardwaj, Ankit Chauhan · 2011 · European Journal of Medicinal Chemistry
21. Cancer immunology—analysis of host and tumor factors for personalized medicine
    Shuji Ogino, Jérôme Galon, Charles S. Fuchs, Glenn Dranoff · 2011 · Nature Reviews Clinical Oncology
22. Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop
    Robert Pirker, Felix J.F. Herth, Keith M. Kerr, Martin Filipits, Miquel Tarón, David R. Gandara, Fred R. Hirsch, Dominique H Grunenwald, Helmut Popper, Egbert Frederik Smit et al. · 2010 · Journal of Thoracic Oncology
23. Cardiotoxicity induced by tyrosine kinase inhibitors
    George S. Orphanos, George N. Ioannidis, Alexandros G. Ardavanis · 2009 · Acta Oncologica
24. Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas
    Zill, Oliver A., Greene, Claire, Sebisanovic, Dragan, Siew, Lai Mun, Leng, Jim, Vu, Mary, Hendifar, Andrew E., Wang, Zhen, Atreya, Chloe E., Kelley, Robin K. et al. · 2015 · Cancer Discovery
25. Acquired resistance to tyrosine kinase inhibitors during cancer therapy
    Jeffrey A. Engelman, Jeffrey E. Settleman · 2008 · Current Opinion in Genetics & Development
26. Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer
    Aleksandra Franovic, Lakshman Gunaratnam, Karlene Smith, Isabelle Robert, David A. Patten, Stephen Lee · 2007 · Proceedings of the National Academy of Sciences
27. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
    Yosuke Togashi, Katsuhiro Masago, Satohiro Masuda, Tomoyuki Mizuno, Masahide Fukudo, Yasuaki Ikemi, Yuichi Sakamori, Hiroki Nagai, Young Hak Kim, Toshiya Katsura et al. · 2012 · Cancer Chemotherapy and Pharmacology
28. Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis
    Zdenko Herceg, Pierre L. Hainaut · 2007 · Molecular Oncology
29. Evolving Concepts in the Pathology and Computed Tomography Imaging of Lung Adenocarcinoma and Bronchioloalveolar Carcinoma
    William David Travis, Kavita Garg, Wilbur A. Franklin, Ignacio Ivan Wistuba, Bradley S. Sabloff, Masayuki Noguchi, Ryutaro Kakinuma, Maureen Frances Zakowski, Michelle S. Ginsberg, Robert F. Padera et al. · 2005 · Journal of Clinical Oncology
30. Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine
    Amanda J. Redig, Pasi Antero Janne · 2015 · Journal of Clinical Oncology
31. Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer
    Wolfram Brugger, Nadja Triller, Maria Błasińska-Morawiec, Stefan Curescu, Raimundas Sakalauskas, Georgy Moiseevich Manikhas, Julien Mazières, Renaud Whittom, Carol Ward, Karen Mayne et al. · 2011 · Journal of Clinical Oncology
32. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2
    Heidi E. Greulich, Bethany Kaplan, Philipp Mertins, Tzu-Hsiu Chen, Kumiko Tanaka, Cai‐Hong Yun, Xiaohong Zhang, Se‐Hoon Lee, Jeonghee Cho, Lauren Ambrogio et al. · 2012 · Proceedings of the National Academy of Sciences
33. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
    Jiannong Li, Uwe Rix, Bin Fang, Yun Bai, Arthur Edwards, Jacques Colinge, Keiryn L. Bennett, Jingchun Gao, Lanxi Song, Steven A. Eschrich et al. · 2010 · Nature Chemical Biology
34. Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor
    Hideharu Kimura, Kazuko Sakai, Tokuzo Arao, Tatsu Shimoyama, Tomohide Tamura, Kazuto Nishio · 2007 · Cancer Science
35. Antitumour immunity regulated by aberrant ERBB family signalling
    Shogo Kumagai, Shohei Koyama, Hiroyoshi Nishikawa · 2021 · Nature reviews. Cancer
36. Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib
    Kenichi Suda, Kenji Tomizawa, Makiko Fujii, Hideki Murakami, Hirotaka Osada, Yoshihiko Maehara, Yasushi Yatabe, Yoshitaka Sekido, Tetsuya Mitsudomi · 2011 · Journal of Thoracic Oncology
37. Diagnosis and Molecular Classification of Lung Cancer
    Jaime Rodriguez‐Canales, Edwin Roger Parra-Cuentas, Ignacio Ivan Wistuba · 2016 · Cancer treatment and research
38. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
    Hajime Asahina, K Yamazaki, Ichiro Kinoshita, Noriaki Sukoh, M. Harada, Hiroshi Yokouchi, Takashi Ishida, Shinji Ogura, T Kojima, Yasushi Okamoto et al. · 2006 · British Journal of Cancer
39. Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma
    James M. Bean, Gregory J. Riely, Marissa N. Balak, Jenifer L. Marks, Marc Ladanyi, Vincent A. Miller, William J. Pao · 2008 · Clinical Cancer Research
40. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
    Toni Michel Brand, Mari Iida, Deric L. Wheeler · 2011 · Cancer Biology & Therapy
41. Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches
    Drilon, Alexander, Wang, Lu, Arcila, Maria E., Balasubramanian, Sohail, Greenbowe, Joel R., Ross, Jeffrey S., Stephens, Phil, Lipson, Doron, Miller, Vincent A., Kris, Mark G. et al. · 2015 · Clinical Cancer Research
42. PIK3CA mutation status in Japanese lung cancer patients
    Osamu Kawano, Hidefumi Sasaki, Katsuhiko Endo, Eriko Suzuki, Hiroshi Haneda, Haruhiro Yukiue, Yoshihiro Kobayashi, Motoki Yano, Yoshitaka Fujii · 2006 · Lung Cancer
43. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer
    Fred R. Hirsch, Marileila Varella‐Garcia, Federico Cappuzzo · 2009 · Oncogene
44. Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanoma
    Ken Wyman, Michael B. Atkins, Victor Prieto, Omar E. Eton, David F. McDermott, Francie J. Hubbard, Christine Byrnes, Kathleen Sanders, Jeffrey Alan Sosman · 2006 · Cancer
45. Oncogene-Selective Sensitivity to Synchronous Cell Death following Modulation of the Amino Acid Nutrient Cystine
    Ioannis Poursaitidis, Xiaomeng Wang, Thomas Crighton, Christiaan F. Labuschagne, David Y. Mason, Shira L. Cramer, Kendra C. Triplett, Rajat Roy, Olivier E. Pardo, Michael J. Seckl et al. · 2017 · Cell Reports
46. An Alternative Inhibitor Overcomes Resistance Caused by a Mutation of the Epidermal Growth Factor Receptor
    Kobayashi, Susumu, Ji, Hongbin, Yuza, Yuki, Meyerson, Matthew, Wong, Kwok-Kin, Tenen, Daniel G., Halmos, Balázs · 2005 · Cancer Research
47. Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR -Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study
    Wen‐Zhao Zhong, Ke‐Neng Chen, Chun Chen, Chundong Gu, Jun Wang, Xue‐Ning Yang, Weimin Mao, Qun Wang, Guibin Qiao, Ying Cheng et al. · 2019 · Journal of Clinical Oncology
48. Large noncoding RNA HOTAIR enhances aggressive biological behavior and is associated with short disease-free survival in human non-small cell lung cancer
    Takayuki Nakagawa, Hiroyuki Endo, Misa Yokoyama, Jiro Abe, Keiichi Tamai, Nobuyuki Tanaka, Ikuro Sato, Satomi Takahashi, Takashi Kondo, Kennichi Satoh · 2013 · Biochemical and Biophysical Research Communications
49. Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens
    Colin C. Pritchard, Stephen J. Salipante, Karen M. Koehler, Christina Smith, Sheena M. Scroggins, Brent Lee Wood, David Wu, Ming K. Lee, Suzanne M. Dintzis, Andrew Adey et al. · 2013 · Journal of Molecular Diagnostics
50. New Paradigms in Anticancer Therapy: Targeting Multiple Signaling Pathways With Kinase Inhibitors
    Sandrine J. Faivre, Siham Djelloul, Éric Raymond · 2006 · Seminars in Oncology
51. Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell–like Properties in Cancer Cells
    Kazuhiko Shien, Shinichi Toyooka, Hiromasa Yamamoto, Junichi Soh, Masaru Jida, Kelsie L. Thu, Shinsuke Hashida, Yuho Maki, Eiki Ichihara, Hiroaki Asano et al. · 2013 · Cancer Research
52. Pharmacogenetics and drug development: the path to safer and more effective drugs
    Allen D. Roses · 2004 · Nature Reviews Genetics
53. Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non–Small-Cell Lung Cancer
    Hua Bai, Li Mao, hang Shu Wang, Jun Zhao, Lu Yang, T. An, Xin Wang, chun Jian Duan, na Mei Wu, zhi Qing Guo et al. · 2009 · Journal of Clinical Oncology
54. EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1–Independent and HIF-1–Dependent Mechanisms
    Nabendu Pore, Zibin Jiang, Anjali Gupta, George J. Cerniglia, Gary D. Kao, Amit M. Maity · 2006 · Cancer Research
55. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
    Cappuzzo, F., Finocchiaro, G., Rossi, E., Jänne, P.A., Carnaghi, C., Calandri, C., Bencardino, K., Ligorio, C., Ciardiello, F., Pressiani, T. et al. · 2008 · Annals of Oncology
56. IL-6 involvement in epithelial cancers
    Zachary T. Schafer, Joan S. Brugge · 2007 · Journal of Clinical Investigation
57. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
    Michael Hölzel, Anton Bovier, Thomas Tüting · 2013 · Nature reviews. Cancer
58. Airway PI3K Pathway Activation Is an Early and Reversible Event in Lung Cancer Development
    Adam M Gustafson, Raffaella Soldi, Christina Anderlind, Mary Beth Scholand, Jun Qian, Xiaohui Zhang, Kendal G. Cooper, Darren Walker, Annette M. McWilliams, Gang Liu et al. · 2010 · Science Translational Medicine
59. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib
    Fred R. Hirsch, Marileila Varella‐Garcia, Federico Cappuzzo, J. McCoy, Lynne Bemis, Ana C. Xavier, Rafał Dziadziuszko, Paul H. Gumerlock, Kari Chansky, Howard West et al. · 2007 · Annals of Oncology
60. EGFR Tyrosine Kinase Domain Mutations Are Detected in Histologically Normal Respiratory Epithelium in Lung Cancer Patients
    Ximing Tang, Hisayuki Shigematsu, Benjamin Nebiyou Bekele, Jack A. Roth, John Dorrance Minna, Waun Ki Hong, Adi F. Gazdar, Ignacio Ivan Wistuba · 2005 · Cancer Research
61. Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer
    Shirin Khambata‐Ford, Christopher T. Harbison, Lowell L. Hart, M. Awad, Lian Xu, Christine E. Horak, Shaker R. Dakhil, Robert C. Hermann, Thomas James Lynch, Martin R. Weber · 2010 · Journal of Clinical Oncology
62. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer
    April F. Eichler, Kristopher Thomas Kahle, D. L. Wang, Victoria A. Joshi, Henning Willers, J. A. Engelman, Thomas James Lynch, Lecia Van Dam Sequist · 2010 · Neuro-Oncology
63. Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer
    Alexandre F. Aissa, Abul Bashar Mir Md. Khademul Islam, Majd Ariss, Cammille C. Go, Alexandra E. Rader, Ryan D. Conrardy, Alexa M Gajda, Carlota Rubio-Pérez, Klara Valyi‐Nagy, Mary M. Pasquinelli et al. · 2021 · Nature Communications
64. The cancer genome atlas pan-cancer analysis project
    Mills, Gordon B., Mills Shaw, Kenna R., Shmulevich, Ilya, Joshua M. Stuart, Ellrott, Kyle, Chris Sander, The Cancer Genome Atlas Research Network, Collisson, Eric A., Ozenberger, Brad A., Weinstein, John N. · 2019 · Europe PMC (PubMed Central)
65. Pathogenesis of NUT Midline Carcinoma
    Christopher Alexander French · 2011 · Annual Review of Pathology Mechanisms of Disease
66. Quantitative breath analysis of volatile organic compounds of lung cancer patients
    Geng Song, Tao Qin, Hu Liu, Guobing Xu, Yue-Yin Pan, Fuxing Xiong, Kangsheng Gu, Guoping Sun, Zhendong Chen · 2009 · Lung Cancer
67. Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer
    Matthew J. Niederst, Jeffrey A. Engelman · 2013 · Science Signaling
68. EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases
    Katharina Schmid, Natalie Oehl, Fritz Wrba, Robert Pirker, Christine Pirker, Martin Filipits · 2009 · Clinical Cancer Research
69. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib
    Jackman, David M., Holmes, Alison J., Lindeman, Neal, Wen, Patrick Y., Kesari, Santosh, Borras, Ana M., Bailey, Christopher, de Jong, Francisca, Jänne, Pasi A., Johnson, Bruce E. · 2006 · Journal of Clinical Oncology
70. MicroRNA regulation of core apoptosis pathways in cancer
    Raquel T. Lima, Sara Busacca, Gabriela M. Almeida, Giovanni Gaudino, Dean Anthony Fennell, M. Helena Vasconcelos · 2010 · European Journal of Cancer
71. Multiple Oncogenic Changes (K-RASV12, p53 Knockdown,Mutant EGFRs, p16Bypass, Telomerase) Are Not Sufficient to Confer a Full Malignant Phenotype on Human Bronchial Epithelial Cells
    Mitsuo Sato, Melville Bailey Vaughan, Luc Girard, Michael Peyton, Woochang Lee, David S. Shames, Ruben D. Ramirez, Noriaki Sunaga, Adi F. Gazdar, Jerry W. Shay et al. · 2006 · Cancer Research
72. Epidermal Growth Factor Receptors Harboring Kinase Domain Mutations Associate with the Heat Shock Protein 90 Chaperone and Are Destabilized following Exposure to Geldanamycins
    Takeshi Shimamura, April M. Lowell, Jeffrey A. Engelman, Geoffrey Ira Shapiro · 2005 · Cancer Research
73. Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non–Small-Cell Lung Cancer
    Adrian Gerold Sacher, Suzanne Eleanor Dahlberg, Jennifer C. Heng, Stacy L. Mach, Pasi Antero Janne, Geoffrey R. Oxnard · 2015 · JAMA Oncology
74. Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study
    Russell J. Schilder, Michael W. Sill, Xiaowei Chen, Kathleen M. Darcy, Steven L. Decesare, George S. Lewandowski, Roger B. Lee, Cletus A. Arciero, Hong Wu, Andrew K. Godwin · 2005 · Clinical Cancer Research
75. Protein kinase inhibitors: contributions from structure to clinical compounds
    Louise Napier Johnson · 2009 · Quarterly Reviews of Biophysics
76. Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells
    Kaisa Erjala, Maria Sundvall, Teemu T. Junttila, Na Zhang, Mika Savisalo, Pekka Mali, Jarmo A.J. Kulmala, Jaakko O. Pulkkinen, Reidar A. Grenman, Klaus Elenius · 2006 · Clinical Cancer Research
77. Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
    Ramaswamy Govindan, Robert Arthur Kratzke, James E. Herndon, Gloria A. Niehans, Robin T. Vollmer, Dorothy M. Watson, Mark R. Green, Hedy Lee Kindler, on behalf of the Cancer and Leukemia Group B (CALGB 30101) · 2005 · Clinical Cancer Research
78. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors
    Hongbin Ji, Xiaojun Zhao, Yuki Yuza, Takeshi Shimamura, Danan Li, Alexei I. Protopopov, Boonim L. Jung, Kate L. McNamara, Huili Xia, Karen A. Glatt et al. · 2006 · Proceedings of the National Academy of Sciences
79. NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
    Phillip G. Febbo, Marc Ladanyi, Kenneth Aldape, Angelo Michael De Marzo, M. Elizabeth H. Hammond, Daniel F. Hayes, Anthony John Iafrate, Robin Kate Kelley, Guido Marcucci, Shuji Ogino et al. · 2011 · Journal of the National Comprehensive Cancer Network
80. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer: A Review
    Sacher, Adrian G., Gandhi, Leena · 2016 · JAMA Oncology
81. Targeted therapy in cancer
    Apostolia Maria Tsimberidou · 2015 · Cancer Chemotherapy and Pharmacology
82. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer
    Julian Schardt, Manfred Meyer, Claudia H. Hartmann, Falk Schubert, Oleg Schmidt‐Kittler, Christine Fuhrmann, Bernhard Michael Polzer, Marco Petronio, Roland Eils, Christoph A. Klein · 2005 · Cancer Cell
83. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
    Raymond A. Pagliarini, Wenlin Shao, William R. Sellers · 2015 · EMBO Reports
84. Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions
    Martin L. Sos, Kathrin Michel, Thomas Zander, Jonathan M. Weiss, Peter Frommolt, Martin Peifer, Danan Li, Roland Tillmann Ullrich, Mirjam Koker, Florian Fischer et al. · 2009 · Journal of Clinical Investigation
85. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas
    Hidenori Fukuoka, Odelia B. Cooper, Anat Ben-Shlomo, Adam N. Mamelak, Song-Guang Ren, D Bruyette, Shlomo K. Melmed · 2011 · Journal of Clinical Investigation
86. Genomic Medicine–Progress, Pitfalls, and Promise
    Jay Shendure, Gregory M. Findlay, Matthew W. Snyder · 2019 · Cell
87. Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma
    Takayuki Kosaka, Yasushi Yatabe, Ryoichi Onozato, Hiroyuki Kuwano, Tetsuya Mitsudomi · 2009 · Journal of Thoracic Oncology
88. Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
    Fleur Broekman · 2010 · World Journal of Clinical Oncology
89. Genetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer
    Christine A. Pratilas, Aphrothiti J. Hanrahan, Ensar Halilovic, Yogindra Persaud, Junichi Soh, Dhananjay Arun Chitale, Hisayuki Shigematsu, Hiromasa Yamamoto, Ayana Sawai, Manickam Janakiraman et al. · 2008 · Cancer Research
90. Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
    Andrew B. Lassman, Michael R. Rossi, Jeffrey R. Razier, Lauren E. Abrey, Frank Scott Lieberman, Chelsea N. Grefe, Kathleen R. Lamborn, William J. Pao, Alan H. Shih, John G. Kuhn et al. · 2005 · Clinical Cancer Research
91. Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
    Tatsuya Nagano, Motoko Yoshikawa TACHIHARA, Yoshihiro Nishimura · 2018 · Cells
92. Prognostic Significance of Adenocarcinoma In Situ, Minimally Invasive Adenocarcinoma, and Nonmucinous Lepidic Predominant Invasive Adenocarcinoma of the Lung in Patients With Stage I Disease
    Kyuichi Kadota, Jonathan Villena‐Vargas, Akihiko Yoshizawa, Noriko Motoi, Camelia S. Sima, Gregory J. Riely, Valerie W. Rusch, Prasad S. Adusumilli, William David Travis · 2014 · The American Journal of Surgical Pathology
93. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib
    Kazuya Taniguchi, Jiro Okami, Ken Kodama, Masahiko Higashiyama, Kikuya Kato · 2008 · Cancer Science
94. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop
    K E Ware, Trista K. Hinz, Emily K. Kleczko, Katherine R. Singleton, Lindsay A. Marek, Barb Helfrich, Christopher T. Cummings, Douglas K. Graham, David P. Astling, Aik Choon Tan et al. · 2013 · Oncogenesis
95. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
    Bart Neyns, Jan Sadones, Eric J. Joosens, Frank Bouttens, Luc Verbeke, Jean‐François Baurain, Lionel A. D'Hondt, Theo Strauven, C. Chaskis, Pieter In 'T Veld et al. · 2009 · Annals of Oncology
96. Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation
    Sae‐Won Han, Tae‐You Kim, Yoon Kyung Jeon, Pil Gyu Hwang, Seock‐Ah Im, Kyung-Hun Lee, Jee Hyun Kim, Dong‐Wan Kim, Dae Seog Heo, Noe Kyeong Kim et al. · 2006 · Clinical Cancer Research
97. Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non–small Cell Lung Cancer Cells to Treatment with Gefitinib
    Floriana Morgillo, Woo-Young Kim, Edward S. Kim, Fortunato Ciardiello, Waun Ki Hong, Ho‐Young Lee · 2007 · Clinical Cancer Research
98. Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer
    Maria C. Villarroel, N.V. Rajeshkumar, Ignacio Garrido‐Laguna, Ana De Jesus‐Acosta, Siân Jones, Anirban Maitra, Ralph H. Hruban, James R. Eshleman, Alison P. Klein, Daniel A. Laheru et al. · 2010 · Molecular Cancer Therapeutics
99. Molecular Biology of Lung Cancer
    Serge Patrick Nana-Sinkam, Charles A. Powell · 2013 · CHEST Journal
100. Targeting TACE-dependent EGFR ligand shedding in breast cancer
     Paraic A. Kenny, Mina J. Bissell · 2007 · Journal of Clinical Investigation